Serious adverse events · maintenance of remission in Crohn's disease
It is very uncertain whether azathioprine or 6‐mercaptopurine changes serious adverse events compared with placebo (very low certainty).
1 finding from 1 review
Serious adverse events · people with multifocal motor neuropathy
1 finding from 1 review
Serious adverse events · patients with induction of remission in ulcerative colitis
Type I Interferons showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events · adults with strains, sprains, or muscle pull
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Serious adverse events · Adult patients with active ulcerative colitis
Budesonide MMX® 6 mg showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events · Adult patients with active ulcerative colitis
Budesonide MMX® 9 mg showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events · episodic viral wheeze in children
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · episodic viral wheeze in children
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · patients with induction of remission in ulcerative colitis
Etrolizumab showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events · Patients with ankylosing spondylitis
Sulfasalazine showed no clear difference in serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events · patients with osteoporosis
1 finding from 1 review
Serious adverse events · people with chronic gout
Allopurinol showed no clear difference in serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events · Patients with moderately to severely active ulcerative colitis
Vedolizumab showed no clear difference in serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events · people with fatigue in peripheral neuropathy
Ascorbic acid showed no clear difference in serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events · people with fatigue in Guillain‐Barré syndrome
1 finding from 1 review
no estimate extracted
80 participants
GRADE not reported
Serious adverse events · neuropathic pain (two studies found in painful diabetic neuropathy, and one in lumbar radiculopathy)
Topiramate 200 to 400 mg showed no clear difference in serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
RR 0.9 [0.6, 1.3]
1586 participants
Moderate
Serious adverse events · patients with restenosis after percutaneous coronary intervention in coronary heart disease
Xiongshao capsule (XSC) plus conventional western medicine (CWM) leads to lower serious adverse events compared with conventional western medicine (CWM) plus placebo (high certainty).
1 finding from 1 review
Serious adverse events · patients with fibromyalgia
Pregabalin showed no clear difference in serious adverse events compared with placebo at end of treatment (moderate certainty).
1 finding from 1 review
Serious adverse events · patients with primary biliary cirrhosis.
It is very uncertain whether ursodeoxycholic acid changes serious adverse events compared with placebo or no intervention (very low certainty).
1 finding from 1 review
Serious adverse events · High‐risk HIV‐uninfected individuals (including serodiscordant couples, men who have sex with men and sex workers)
TDF+ FTC showed no clear difference in serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review